- Policy & Regulation
- Regional Views
- Regulatory Trackers
- Pink Sheet Originals
- Featured Topics
Latest From Tara Hansen
Oncology Accelerated Approval Withdrawals: Which Indications Need Confirmation Next?
Bookmark
-
Analysis
US FDA’s ‘industry-wide evaluation’ of accelerated approvals has already led to withdrawals of four PD-1/PD-L1 inhibitor indications, with the Oncologic Drugs Advisory Committee set to review another six next week. Over the next two years, an additional five indications may be up for review.
Advertisement